Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)
NCT00989261
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
333
Enrollment
INDUSTRY
Sponsor class
Conditions
Acute Myeloid Leukemia
Interventions
DRUG:
Compound AC220
Sponsor
Daiichi Sankyo